Targeting Dual-specificity Phosphatase 3: a novel therapeutic for arterial thrombosis

The authors describe that DUSP3 inhibition or deficiency may lead to better response in arterial thrombosis. To that effect mimicking this action (inhibition) by a drug molecule may lead to better health outcome for patients suffering from heart attack and Brain strokes.

Read the article at:
http://circ.ahajournals.org/content/131/7/656.abstract


Some excerpts "This phosphatase is highly expressed in human and mouse platelets. Platelets from DUSP3-deficient mice displayed a selective impairment of aggregation and granule secretion mediated by the collagen receptor glycoprotein VI and the C-type lectin-like receptor 2. DUSP3-deficient mice were more resistant to collagen- and epinephrine-induced thromboembolism compared with wild-type mice and showed severely impaired thrombus formation on ferric chloride–induced carotid artery injury. Intriguingly, bleeding times were not altered in DUSP3-deficient mice. At the molecular level, DUSP3 deficiency impaired Syk tyrosine phosphorylation, subsequently reducing phosphorylation of phospholipase Cγ2 and calcium fluxes. To investigate DUSP3 function in human platelets, a novel small-molecule inhibitor of DUSP3 was developed. This compound specifically inhibited collagen- and C-type lectin-like receptor 2–induced human platelet aggregation, thereby phenocopying the effect of DUSP3 deficiency in murine cells."

Comments